紫杉醇、顺铂方案联合腹腔热灌注化疗对晚期卵巢癌病人免疫功能及生存质量的影响

目的探讨紫杉醇、顺铂方案( TP方案)联合腹腔热灌注化疗对晚期卵巢癌病人免疫功能及生存质量的影响。方法选取 2016年 1月至 2019年 1月南阳市中心医院 72例晚期卵巢癌病人，随机数字表法分为观察组和对照组，各 36例。对照组给予单纯紫杉醇、顺铂方案静脉化疗，观察组在静脉化疗的基础上，在末次化疗后第 8天进行腹腔热灌注化疗，顺铂用量为 60 mg，每次热灌注化疗时间为 90 min。比较两组病人的 T淋巴细胞亚群检测结果；比较两组病人的生存质量改善情况、不良反应发生情况以及 1年的生存情况。结果两组病人治疗前分化簇 3阳性( CD3+)、分化簇 4阳性( CD4+)、分化簇 8阳性( CD8+)及 CD4+/CD8+比例差异无统计学意义( P>0.05)，治疗后 6个月两组 CD3+，CD4+，CD4+/CD8+高于治疗前( P<0.05)，而 CD8+低于治疗前( P<0.05)治疗后 6个月观察组 CD3+CD4+%，CD4+/CD8+高于对照组( P<0.05)CD8+低于对照组( P<0.05)。治疗前两组 Ka mofsky(KPS)生，活状态量表评分差异无统计，学意义( P>0.05)，治疗后观察组 KPS评分，较治疗前增高(P<0.05)，且显著高于对照组( P<0.05)。观察组化疗后生存质量提高的比例为 63.89%，高于对照组的 38.89%(P<0.05)；观察组胃肠道反应发生率为

Effect of paclitaxel, cisplatin regimen combined with intraperitoneal hyperthermic perfusion chemotherapy on immune function and quality of life in patients with advanced ovarian cancer

Objective To investigate the effect of paclitaxel, cisplatin (TP) regimen combined with intraperitoneal hyperthermic per fusion chemotherapy on immune function and quality of life in patients with advanced ovarian cancer.Methods A total of 72 patientswith advanced ovarian cancer in Nanyang Central Hospital from January 2016 to January 2019 were selected and randomly divided intoan observation group and a control group, with 36 cases in each group. The control group was given intravenous chemotherapy with TPalone, and the observation group was given intraperitoneal hyperthermic perfusion chemotherapy on the basis of intravenous chemother apy on the 8th day after the last chemotherapy. The dosage of cisplatin was 60 mg and the time of each hyperthermic perfusion chemo therapy was 90min. The detection results of T lymphocyte subsets of the two groups of patients were compared, the improvement of thequality of life, the occurrence of adverse reactions and the 1-year survival of the two groups of patients were compared.Results Before treatment, there was no significant difference in cluster 3 positive (CD3+), cluster 4 positive (CD4+), cluster 8 positive (CD8+) and CD4+/CD8+ ratio between the two groups (P>0.05). Six months after treatment, CD3+, CD4+, CD4+/CD8+ ratio in the two groups were higher than before treatment (P<0.05), while CD8+ was lower than before treatment (P<0.05). Meanwhile, CD3+, CD4+, CD4+/CD8+ ratio in the observation group were higher than those in the control group (P<0.05), and CD8+ was lower than that in the control group (P<0.05). Before treatment, there was no significant difference in Kamofsky (KPS) living state scale score between the two groups (P>0.05), but af ter treatment, the KPS score in the observation group was higher than that before treatment (P<0.05), and was significantly higher than that in the control group (P<0.05). The improvement rate of quality of life in the observation group after chemotherapy was 63.89%,